Pfizer (Austria)

Recent papers from Pfizer (Austria)

1. Incidence of medically attended Lyme borreliosis across endemic regions of six European countries (BOLD): a prospective multicentre active surveillance studyThe Lancet Regional Health - Europe · 2026
2. Risk Analysis from the Burden of Lyme Disease (BOLD) StudyPathogens · 2026
3. Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REALJournal of Dermatological Treatment · 2026
4. Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) StudyPathogens · 2026
5. Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer in the real-world setting: Results from the PERFORM study.Journal of Clinical Oncology · 2026
6. Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 yearsJournal of the European Academy of Dermatology and Venereology · 2026
7. Correction: Müller et al. Does the Vaccination Against Tick-Borne Encephalitis Offer Good Value for Money for Incidence Rates Below the WHO Threshold for Endemicity? A Case Study for Germany. Vaccines 2024, 12, 1165Vaccines · 2026
8. P-180. Tick-borne Encephalitis (TBE) in International Travelers and TBE Vaccine Recommendations for Travelers to EuropeOpen Forum Infectious Diseases · 2026
9. Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Dermatology and Therapy · 2025
10. Factors influencing Lyme borreliosis risk perception in Europe: a cross-sectional multi-country survey studyBMC Public Health · 2025
11. Tick-borne encephalitis vaccine effectiveness and public health impact in the Baltic countries of Estonia, Latvia, and Lithuania, 2019-2023IJID Regions · 2025
12. Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate‐to‐Severe Atopic DermatitisAllergy · 2025
13. Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022Scientific Reports · 2025
14. Lyme neuroborreliosis in Japan: Borrelia burgdorferi sensu lato as a cause of meningitis of previously undetermined etiology in hospitalized patients outside of the island of Hokkaido, 2010–2021European Journal of Neurology · 2025
15. Does the Vaccination against Tick-Borne Encephalitis Offer Good Value for Money for Incidence Rates below the WHO Threshold for Endemicity? A Case Study for GermanySHILAP Revista de lepidopterología · 2024
16. Estimated incidence of symptomatic Lyme borreliosis cases in five southern coastal counties in Norway, 2022Apmis · 2024
17. Incidence of symptomatic Lyme borreliosis in nine European countriesInternational Journal of Infectious Diseases · 2024
18. Excess Healthcare Costs and Resource Utilisation of Lyme Borreliosis in Germany: A Propensity Score–Matched Cohort StudyZoonoses and Public Health · 2024
19. Incidence of symptomatic Borrelia burgdorferi sensu lato infection in Romania, 2018−2023Parasites & Vectors · 2024
20. Publicly available surveillance data on tick-borne encephalitis in Europe, 2023Ticks and Tick-borne Diseases · 2024